Aspira Women’s Health, Inc. to Report Third Quarter 2020 Financial Results on November 12th

Rhea-AI Summary

Aspira Women’s Health, Inc. (AWH) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close. An investor conference call will follow at 4:30 p.m. ET. The company focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic disease management. Aspira is positioned to address ethnic disparities in health outcomes through its product portfolio, including OVA1 plus and ASPIRA GenetiX testing.

Positive

• Focused on closing ethnic disparity gaps in ovarian cancer assessment.
• Innovative product portfolio including OVA1® plus and ASPIRA GenetiX™.

Negative

• None.

AUSTIN, Texas, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, November 12th @ 4:30pm ET
Domestic:	877-407-4018
International:	201-689-8471
Conference ID:	13712253
Webcast:	http://public.viavid.com/index.php?id=142095

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as, Vermillion inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1^® and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

When will Aspira Women’s Health report its Q3 2020 financial results?

Aspira Women’s Health will report its Q3 2020 financial results on November 12, 2020, after market close.

What time is the investor conference call for Aspira Women’s Health?

The investor conference call for Aspira Women’s Health is scheduled for 4:30 p.m. ET on November 12, 2020.

What is the focus of Aspira Women’s Health?

Aspira Women’s Health focuses on bio-analytical solutions for women's health, particularly in ovarian cancer risk assessment and pelvic diseases.